. 2018 Aug 24;32(12):1173–1181. doi: 10.1007/s40263-018-0553-1

Table 2.

Change from baseline for GCS and the seven cognitive domains at 1 and 2 years of natalizumab treatment (N = 52)

	1 year			2 years
	Mean	95% CI	p value^a	Mean	95% CI	p value^a
GCS	2.06	− 0.12, 4.24	0.064	3.43	1.18, 5.69	0.003
Memory	0.94	− 2.30, 4.18	0.570	3.44	0.97, 5.92	0.006
Executive function	1.68	− 1.75, 5.11	0.337	3.21	− 0.24, 6.66	0.068
Visual-spatial processing	1.39^a	− 2.39, 5.16	0.471	4.31	0.54, 8.08	0.025
Verbal functioning	6.36	1.75, 10.97	0.007	3.19	− 2.28, 8.66	0.253
Attention	1.00	− 2.11, 4.11	0.529	4.27	0.76, 7.79	0.017
Information processing speed	2.54^b	− 0.59, 5.68	0.112	5.15^b	1.96, 8.34	0.002
Motor function	1.02^a	− 1.87, 3.92	0.487	0.05^a	− 3.38, 3.48	0.976

p Value for change based on generalized estimating equation model of change with treatment group, visit, and their interaction as effects, adjusted for baseline Expanded Disability Status Scale score and baseline age

GCS global cognitive score, CI confidence interval

^an = 51

^bn = 49